Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT). This grand round series will emphasize the burden of CMV in kidney transplantation and HSCT, review the benefits and limitations of current antiviral agents, and discuss the role of novel antivirals (e.g., letermovir and maribavir) for managing CMV. Case studies will demonstrate how to integrate novel antivirals into clinical practice to improve quality of care and outcomes.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2025-02-24 06:00:00
- End Date: 2025-02-24 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Merck (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Limited
- Specialty: Infectious Disease, Internal Medicine
Subscribe
Login
0 Comments
Oldest